DDInter1082 DDInter642
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022.
Enfortumab vedotin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lumacaftor
Enfortumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Enfortumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Enfortumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Enfortumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Enfortumab vedotin may lead to a major life threatening interaction when taken with Fingolimod
Enfortumab vedotin may lead to a major life threatening interaction when taken with Upadacitinib